<DOC>
	<DOCNO>NCT01870843</DOCNO>
	<brief_summary>The purpose study evaluate impact escitalopram quality life social functionality patient major depressive disorder anxiety symptom .</brief_summary>
	<brief_title>A Study Evaluate Impact Escitalopram Quality Life Social Functionality Patients With Major Depressive Disorder With Anxiety Symptom</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , multi-center , prospective ( study participant identify follow forward time outcome study ) , single-arm ( participant receive one intervention ) study . Approximately 260 participant enrol study . This study consist two phase : screen phase treatment phase . In treatment phase , participant receive escitalopram 8 week : escitalopram 10 mg per day 1 week dose escitalopram flexibly adjust maximum 20 mg per day next 7 week , base investigator 's clinical judgment . Safety evaluation include assessment adverse event , clinical laboratory test , electrocardiogram , vital sign , physical examination monitor throughout study . The total study duration approximately 2 year .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Diagnosis major depressive disorder accord American Psychiatric Association 's Diagnostic Statistical ManualIV , Text Revision ( DSMIVTR ) diagnostic criterion Minimum score 9 Sheehan Disability Scale Minimum score 14 Hamilton Anxiety Scale History primary comorbid diagnose schizophrenia , schizoaffective disorder , bipolar disorder , dementia Presence unstable serious illness and/or clinically significant renal hepatic impairment , seizure disorder disease may detrimental participant study Participant continuously take psychoactive substance , antidepressant , anxiolytic , Monoamine oxidase inhibitor , psychoactive herbal remedy , lithium , electroconvulsive therapy , carbamazepine past 2 week baseline visit Diagnosis major depressive disorder currently require treatment systematically within past 2 month baseline Receiving pharmacological treatment , disallow current approve Chinese summary product characteristic escitalopram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Depressive Disorder , Major</keyword>
	<keyword>Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Quality life</keyword>
	<keyword>Social functionality</keyword>
</DOC>